| Literature DB >> 36067266 |
Jun Jie Wong1,2, Foo Kiong Ho1, Pei Yi Choo1, Kelvin K L Chong1,3, Chee Meng Benjamin Ho4, Ramesh Neelakandan5, Damien Keogh1, Timothy Barkham6,7, John Chen6, Chuan Fa Liu5, Kimberly A Kline1,5,8.
Abstract
Wound infections are often polymicrobial in nature, biofilm associated and therefore tolerant to antibiotic therapy, and associated with delayed healing. Escherichia coli and Staphylococcus aureus are among the most frequently cultured pathogens from wound infections. However, little is known about the frequency or consequence of E. coli and S. aureus polymicrobial interactions during wound infections. Here we show that E. coli kills Staphylococci, including S. aureus, both in vitro and in a mouse excisional wound model via the genotoxin, colibactin. Colibactin biosynthesis is encoded by the pks locus, which we identified in nearly 30% of human E. coli wound infection isolates. While it is not clear how colibactin is released from E. coli or how it penetrates target cells, we found that the colibactin intermediate N-myristoyl-D-Asn (NMDA) disrupts the S. aureus membrane. We also show that the BarA-UvrY two component system (TCS) senses the environment created during E. coli and S. aureus mixed species interaction, leading to upregulation of pks island genes. Further, we show that BarA-UvrY acts via the carbon storage global regulatory (Csr) system to control pks expression. Together, our data demonstrate the role of colibactin in interspecies competition and show that it is regulated by BarA-UvrY TCS during interspecies competition.Entities:
Mesh:
Substances:
Year: 2022 PMID: 36067266 PMCID: PMC9481169 DOI: 10.1371/journal.ppat.1010766
Source DB: PubMed Journal: PLoS Pathog ISSN: 1553-7366 Impact factor: 7.464
List of bacterial strains and plasmids used in this study.
| Bacterial Strains | Description | References |
|---|---|---|
|
| ||
| UTI89 | Uropathogenic clinical isolate | [ |
| CFT073 | Uropathogenic clinical isolate | [ |
| MG1655 | [ | |
| Nissle 1917 | Non-pathogenic gut isolate | [ |
| UTI89 Δ | This study | |
| UTI89 Δ | This study | |
| UTI89 Δ | This study | |
| UTI89-pCsrA | UTI89 (pTrc99a-CsrA) | This study |
| UTI89-pCsrB | UTI89(pTrc99a-CsrB) | This study |
| UTI89 ClbRmut | UTI89 strain with GGA bases mutated in | This study |
| This study | ||
| This study | ||
|
| ||
| RN001 | [ | |
| HG001 | RN001 derivative, | [ |
| RN6734 | 8325–4 derivative, | [ |
| MN8 | Clinical isolate of toxic shock syndrome | [ |
| USA300 LAC | Community-associated MRSA USA300 | [ |
| JE2 | USA300 LAC, p01 and p03 cured | [ |
| RN450 | Prophage cured | [ |
| USA300 LAC-GFP | USA300 LAC, pALC1420 GFP+ | [ |
| RN4220 | [ | |
| USA300-ClbS | USA300 LAC (pJC-2343-ClbS) | This study |
|
| ||
| pKM208 | Red recombinase expressing plasmid; AmpR | [ |
| pSLC-217 | P | [ |
| pTrc99a | [ | |
| pJC1213 | [ | |
| pJC2343 | pJC1213, P | This study |
| pTrc99a-CsrA | This study | |
| pTrc99a-CsrB | This study | |
| pJC-2343 | This study | |
| pJC-2343-ClbS | This study | |